Omics-based biomarkers as useful tools in metabolic dysfunctionassociated steatotic liver disease clinical practice:How far are we?
作者机构：Instituto de Medicina Traslacional e Ingeniería Biomédica-Consejo Nacional de Investigaciones Científicas y Técnicas-Instituto Universitario del Hospital Italiano-Hospital Italiano de Buenos AiresCiudad Autónoma de Buenos Aires C1199ACLArgentina Consejo Nacional de Investigaciones Científicas y TécnicasCiudad Autónoma de Buenos Aires C1425FQBArgentina Liver UnitHospital Italiano de Buenos AiresCiudad Autónoma de Buenos Aires C1199DFArgentina Department of ResearchHospital Italiano de Buenos AiresCiudad Autónoma de Buenos Aires C1199DFArgentina
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2024年第30卷第14期
页 面：1982-1989页
核心收录：
基 金：Supported by PIP-CONICET 2021-2023 grant,No.11220200100875CO PICT-2020-Serie,No.A-00788 and“Florencio Fiorini Foundation”grants.
主 题：Metabolic dysfunction-associated steatotic liver disease Non-alcoholic steatohepatitis Biomarker Risk stratification Omics
摘 要：Unmet needs exist in metabolic dysfunction-associated steatotic liver disease(MASLD)risk stratification.Our ability to identify patients with MASLD with advanced fibrosis and at higher risk for adverse outcomes is still limited.Incorporating novel biomarkers could represent a meaningful improvement to current risk predictors.With this aim,omics technologies have revolutionized the process of MASLD biomarker discovery over the past decades.While the research in this field is thriving,much of the publication has been haphazard,often using single-omics data and specimen sets of convenience,with many identified candidate biomarkers but lacking clinical validation and utility.If we incorporate these biomarkers to direct patients’management,it should be considered that the roadmap for translating a newly discovered omics-based signature to an actual,analytically valid test useful in MASLD clinical practice is rigorous and,therefore,not easily accomplished.This article presents an overview of this area’s current state,the conceivable opportunities and challenges of omics-based laboratory diagnostics,and a roadmap for improving MASLD biomarker research.
维普期刊数据库